Clinical Trials Logo

Clinical Trial Summary

This phase 2B, placebo-controlled, randomized, observer-blinded trial will evaluate the safety, tolerability, and immunogenicity of the investigational multivalent group B streptococcus vaccine administered concomitantly with Tdap in healthy nonpregnant women 18 through 49 years of age.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04766086
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date August 12, 2022
Completion date April 27, 2023

See also
  Status Clinical Trial Phase
Completed NCT03765073 - Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants Phase 2